[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Istanbul Training and Research Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":326},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,73,92,120,150,180,210,243,270,297],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652248","diffusion-weighted-mri-findings-in-fetuses-with-and-without-fetal-growth-restriction-100652248",false,"NCT07769957","DIFFUSION WEIGHTED MRI FINDINGS IN FETUSES WITH AND WITHOUT FETAL GROWTH RESTRICTION","COMPARISON OF DIFFUSION WEIGHTED MAGNETIC RESONANCE IMAGING FINDINGS IN FETUSES WITH AND WITHOUT FETAL GROWTH RESTRICTION: THE IMPACT OF MIDDLE CEREBRAL ARTERY DOPPLER FINDINGS","Inclusion Criteria:\n\n* Singleton pregnancy\n* Gestational age between 28 and 38 weeks\n* Maternal age between 18 and 45 years\n* For the FGR groups: estimated fetal weight (EFW) below the 10th percentile and\u002For abdominal circumference (AC) below the 10th percentile\n* For the control group: EFW and AC between the 10th and 90th percentiles, normal fetal Doppler findings, and no major structural anomaly on fetal anatomical examination\n* Written informed consent for participation in the study\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Major fetal structural anomaly or diagnosed chromosomal abnormality\n* Contraindication to MRI, such as an MRI-incompatible implant\n* Maternal uncontrolled diabetes mellitus, significant thyroid disease, severe uncontrolled chronic hypertension, or other significant systemic chronic disease\n* Maternal age below 18 or above 45 years\n* Inability or unwillingness to provide informed consent or cooperate with study procedures",true,"FEMALE","18 Years","45 Years",{"count":21,"type":22},120,"ESTIMATED","1 Day","OBSERVATIONAL","This prospective observational study aims to compare fetal brain diffusion-weighted magnetic resonance imaging (DWI) findings in fetuses with and without fetal growth restriction (FGR) and to evaluate the association between middle cerebral artery (MCA) Doppler findings and regional apparent diffusion coefficient (ADC) values.\n\nParticipants will be classified into three groups: fetuses with FGR and normal MCA Doppler findings, fetuses with FGR and MCA Doppler redistribution, and appropriately grown for gestational age (AGA) healthy control fetuses with normal Doppler findings. Fetal DWI will be performed using a 1.5-Tesla MRI scanner, and ADC values will be measured in predefined brain regions, including the frontal, occipital, and temporal white matter, thalamus, pons, cerebellar hemispheres, and centrum semiovale.\n\nThe primary objective is to compare regional ADC values between fetuses with FGR and healthy controls. The secondary objective is to determine whether ADC values differ between FGR fetuses with normal MCA Doppler findings and those with MCA Doppler redistribution. The study also aims to evaluate the relationship between ADC values, gestational age, fetal biometric measurements, and Doppler parameters.",[27],"Fetal Growth Restriction (FGR)",[29,30,31,32,33],"Fetal Growth Restriction","Diffusion-Weighted Imaging","Fetal MRI","MCA Doppler","Cerebral Redistribution","RECRUITING","2026-08-18",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":38},"2026-03-26",{"date":42,"type":22},"2030-12",{"name":44,"class":45},"Istanbul Training and Research Hospital","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100652490","association-of-maternal-thyroid-function-and-anxiety-with-fetal-cardiotocography-parameters-in-high-risk-pregnancies-100652490","NCT07774949","Association of Maternal Thyroid Function and Anxiety With Fetal Cardiotocography Parameters in High-Risk Pregnancies","Association Between Maternal Thyroid Functions, Anxiety Levels, and Fetal Cardiotocography Parameters in High-Risk Pregnancies","Inclusion Criteria:\n\n* Singleton pregnancy at 32 weeks of gestation or later\n* Pregnancy being followed as a high-risk pregnancy\n* Age between 18 and 45 years\n* Availability of routine thyroid function test results and non-stress test assessment\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Gestational age below 32 weeks\n* Multiple pregnancy\n* Fetal conditions that may affect interpretation of the non-stress test tracing\n* Acute maternal infection\n* Presence of an acute obstetric condition\n* Previously diagnosed psychiatric disorder\n* Current use of psychiatric medication\n* Age younger than 18 years or older than 45 years",{"count":55,"type":22},150,"This prospective observational study aims to investigate the association between maternal thyroid function, maternal anxiety levels, and fetal cardiotocography parameters in high-risk pregnancies. Pregnant women at 32 weeks of gestation or later who are followed in the perinatology outpatient clinic for high-risk pregnancy will be included.\n\nMaternal thyroid function test results, including thyroid-stimulating hormone (TSH) and free thyroxine (fT4), obtained as part of routine clinical care will be recorded. Maternal anxiety will be assessed using the Beck Anxiety Inventory. Fetal well-being will be evaluated using a routine 20-minute non-stress test (NST), including baseline fetal heart rate, accelerations, reactivity, and the presence of decelerations.\n\nThe associations between maternal anxiety scores, thyroid hormone levels and thyroid status, and fetal cardiotocography parameters will be analyzed. Sociodemographic and obstetric characteristics will also be evaluated in relation to these parameters.",[58],"High-risk Pregnancy",[60,61,62,63,64],"High-risk pregnancy","Maternal anxiety","Thyroid dysfunction","Cardiotocography","Beck Anxiety Inventory","2026-08-15",{"date":67,"type":38},"2026-08-19",{"date":69,"type":38},"2026-03-27",{"date":71,"type":22},"2028-12",{"name":44,"class":45},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":80,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":46},"100652304","fetal-health-locus-of-control-maternal-anxiety-and-cardiotocography-in-high-risk-pregnancies-100652304","NCT07774936","Fetal Health Locus of Control, Maternal Anxiety, and Cardiotocography in High-Risk Pregnancies","The Relationship Between Fetal Health Locus of Control Perceptions, Anxiety Levels, and Fetal Cardiotocography Parameters in High-Risk Pregnant Women","Inclusion Criteria:\n\n* Singleton pregnancy at 32 weeks of gestation or later\n* Being followed for a high-risk pregnancy\n* No known diagnosed psychiatric disorder and no current psychiatric medication use\n* Absence of a fetal condition considered likely to affect the NST tracing\n* Maternal age between 18 and 45 years\n\nExclusion Criteria:\n\n* Gestational age below 32 weeks and\u002For multiple pregnancy\n* Presence of a fetal condition considered likely to affect the NST tracing\n* Acute maternal infection or an obstetric emergency\n* Known diagnosed psychiatric disorder and\u002For current psychiatric medication use\n* Maternal age below 18 years or above 45 years",{"count":55,"type":22},"This prospective observational cross-sectional study aims to evaluate the relationships among fetal health locus of control (FHLC) perceptions, maternal anxiety levels, and fetal cardiotocography parameters in high-risk pregnant women. Pregnant women at 32 weeks of gestation or later who undergo routine non-stress testing (NST) at the Perinatology Outpatient Clinic will be invited to participate. On the same day as the routine NST, participants will complete the Fetal Health Locus of Control Scale and the Beck Anxiety Inventory. Associations between FHLC dimensions, maternal anxiety levels, and NST parameters, including baseline fetal heart rate, number of accelerations, reactivity, and presence of decelerations, will be evaluated.",[58],[84,85,86,63],"Fetal Health Locus of Control","Maternal Anxiety","High-Risk Pregnancy",{"date":67,"type":38},{"date":89,"type":38},"2026-04-14",{"date":71,"type":22},{"name":44,"class":45},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":46},"100592838","effectvty-of-chitosan-covered-gauze-in-postpartum-hemorrhagic-obstetric-lacerations-100592838","NCT06998641","EFFECTIVITY OF CHITOSAN COVERED GAUZE IN POSTPARTUM HEMORRHAGIC OBSTETRIC LACERATIONS","Inclusion Criteria:\n\n* Women who delivered at the Department of Obstetrics and Gynecology of Istanbul Training and Research Hospital between March 2025 and March 2027.\n* Age between 18 and 48 years.\n* Presence of a bleeding postpartum obstetric laceration (first- or second-degree) without an anatomical defect requiring surgical repair.\n* Absence of additional conditions that may affect the amount of postpartum bleeding, such as uterine atony or retained placental tissue.\n* Provision of written informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Age younger than 18 years or older than 48 years.\n* Absence of a bleeding postpartum first- or second-degree obstetric laceration meeting the study criteria.\n* Presence of an obstetric laceration with an anatomical defect requiring surgical repair.\n* Presence of additional causes or conditions that may affect postpartum blood loss, such as uterine atony or retained placental tissue.\n* Failure to provide informed consent.","48 Years",{"count":100,"type":22},62,"INTERVENTIONAL",[103],"NA","This study was planned to investigate the efficacy of different treatment methods that can be used in the treatment of hemorrhagic tears that may occur in the postpartum period. The volunteers who will participate in the study will be evaluated during the hospitalization period after delivery and at the end of the puerperium 6 weeks after delivery, in accordance with routine postpartum control examinations. In the treatment of postpartum hemorrhagic tears, the treatment options such as suturing the tears to stop bleeding or applying tampons with bleeding stopping agent (chitosan) and compression effect to the torn area will be determined completely randomly.",[106,107],"Effectiveness of Chitosan Covered Gauze to Stop Bleeding in Post-partum Tears","Comparison of the Effect of Chitosan Covered Gauze With Suturing in Terms of Hemostasis in Post-partum Haemorrhagic Tears",[109,110,111],"chitosan-covered-gauze","post-partum lacerations","obstetrical tears","2026-08-13",{"date":114,"type":38},"2026-08-17",{"date":116,"type":38},"2025-03-01",{"date":118,"type":22},"2027-12",{"name":44,"class":45},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":16,"sex":127,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":131,"conditions":132,"keywords":137,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":46},"100649297","serum-ferroptosis-biomarkers-gpx4-mda-in-alopecia-areata-100649297","NCT07733063","Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata","Evaluation of Serum Ferroptosis Biomarkers (GPX4 and MDA) and Their Relationship With Disease Stage, Clinical Severity, and Trichoscopic Findings in Patients With Alopecia Areata","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years.\n* Formally diagnosed with Alopecia Areata based on clinical and trichoscopic examination.\n* Healthy volunteers with no personal or family history of alopecia or any systemic inflammatory\u002Fautoimmune conditions (for the healthy control group).\n* Patients who have provided written informed consent before any study-related procedures.\n\nExclusion Criteria:\n\n* Use of topical corticosteroids, intralesional steroid injections, or topical calcineurin inhibitors within the last 1 month.\n* Use of systemic immunosuppressive therapies, systemic corticosteroids, or JAK inhibitors within the last 3 months.\n* Presence of any other co-existing active autoimmune or inflammatory skin diseases (e.g., Psoriasis, Vitiligo, or active autoimmune thyroiditis with elevated TSH levels).\n* History of malignancy, active severe infection, chronic hepatic failure, or chronic renal failure.\n* Pregnancy or lactation.\n* History of heavy smoking or uncontrolled\u002Fregular use of antioxidant or vitamin supplements (e.g., Vitamin E, Vitamin C, CoQ10, NMN, resveratrol).","ALL","65 Years",{"count":130,"type":22},156,"This study aims to investigate the potential role of the ferroptosis pathway in the pathogenesis and clinical course of Alopecia Areata (AA). Serum concentrations of two key ferroptosis biomarkers-Glutathione Peroxidase 4 (GPX4), a primary antioxidant enzyme protecting against lipid peroxidation, and Malondialdehyde (MDA), a major end-product of lipid membrane damage-will be quantitatively measured using Enzyme-Linked Immunosorbent Assay (ELISA) kits.\n\nA total of 156 participants will be enrolled, consisting of 104 patients diagnosed with Alopecia Areata (subdivided into acute and chronic cohorts) and 52 age- and sex-matched healthy controls. Serum biomarker levels will be statistically compared among the groups to determine their diagnostic value. Furthermore, these biomarker levels will be correlated with clinical disease extension evaluated via the Severity of Alopecia Tool (SALT) score and objective trichoscopic activity findings (such as black dots, yellow dots, and exclamation mark hairs). The ultimate goal of this cross-sectional study is to evaluate whether serum GPX4 and MDA can serve as reliable objective biomarkers for monitoring disease severity, staging, and trichoscopic activity in Alopecia Areata management.The ultimate goal of this cross-sectional study is to evaluate whether serum GPX4 and MDA can serve as reliable objective biomarkers for monitoring disease severity, staging, and trichoscopic activity in Alopecia Areata management.",[133,134,135,136],"Alopecia Areata(AA)","Alopecia Areata","Alopecia Areata (& Ophiasis)","Alopecia",[138,139,140,141],"ferroptosis","alopecia areata","GPX4","MDA","2026-07-29",{"date":144,"type":38},"2026-07-30",{"date":146,"type":38},"2026-06-01",{"date":148,"type":22},"2027-01-01",{"name":44,"class":45},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":127,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":46},"100645016","ai-based-risk-classification-and-histopathological-subtype-prediction-of-basal-cell-carcinoma-using-dermoscopic-images-100645016","NCT07677124","AI-Based Risk Classification and Histopathological Subtype Prediction of Basal Cell Carcinoma Using Dermoscopic Images","Risk Classification and Prediction of Histopathological Subtypes in Basal Cell Carcinoma Using a CNN-Based Artificial Intelligence Model on Dermoscopic Images","BCC-AI","Inclusion Criteria:\n\n* Patients with histopathologically confirmed basal cell carcinoma.\n* Cases with a specified histopathological subtype.\n* Availability of dermoscopic images with sufficient image quality and resolution for artificial intelligence analysis.\n\nExclusion Criteria:\n\n* Cases without histopathological confirmation of basal cell carcinoma.\n* Cases with unspecified histopathological subtype.\n* Images with insufficient quality or resolution for artificial intelligence analysis.\n* Cases without available dermoscopic images.","0 Years","100 Years",{"count":161,"type":22},2500,"This retrospective observational study aims to develop and evaluate a convolutional neural network (CNN)-based artificial intelligence model for risk classification and histopathological subtype prediction of basal cell carcinoma (BCC) using clinical and dermoscopic images. Histopathologically confirmed BCC cases from a dermatology archive will be included. The primary objective is to assess the diagnostic performance of the CNN model in classifying BCC as low-risk or high-risk. Secondary objectives include predicting histopathological subtypes and comparing the model's performance with that of dermatology physicians. Histopathological diagnosis will serve as the reference standard. All archived data will be anonymized before analysis.",[164],"Basal Cell Carcinoma",[164,166,167,168,169,170,171],"Artificial Intelligence","Convolutional Neural Network","Dermoscopy","Skin Cancer","Histopathological Subtypes","Risk Classification","2026-06-29",{"date":174,"type":38},"2026-06-30",{"date":176,"type":38},"2026-05-22",{"date":178,"type":22},"2027-05-22",{"name":44,"class":45},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":127,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":46},"100622540","correlation-of-dermoscopic-findings-with-histopathological-features-and-invasion-depth-in-cutaneous-squamous-cell-carcinoma-100622540","NCT07384949","Correlation of Dermoscopic Findings With Histopathological Features and Invasion Depth in Cutaneous Squamous Cell Carcinoma","Correlation of Invasion Depth and Histopathological Features With Dermoscopic Findings in Cutaneous Squamous Cell Carcinoma","SCC-DERM","Inclusion Criteria:Age between 18 and 100 years at the time of diagnosis\n\nHistopathologically confirmed cutaneous squamous cell carcinoma\n\nLesions that underwent total surgical excision\n\nHistopathology reports including both tumor differentiation grade and invasion depth\n\nAvailability of dermoscopic images obtained prior to excision\n\nDermoscopic images of sufficient quality for evaluation and image analysis -\n\nExclusion Criteria:\n\nLesions that received any prior treatment, including radiotherapy, chemotherapy, cryotherapy, or other destructive or topical treatments before excision\n\nIncomplete clinical, dermoscopic, or histopathological data\n\nPoor-quality dermoscopic images not suitable for reliable evaluation or segmentation\n\n\\-",{"count":189,"type":22},238,"This is a retrospective study including patients diagnosed with cutaneous squamous cell carcinoma between 2016 and 2025. Demographic, clinical, histopathological, and dermoscopic data were obtained from hospital records. Dermoscopic images taken with the FotoFinder dermoscope were independently evaluated by two dermatologists in a blinded manner. In addition, images were labeled using computer software and analyzed to measure the proportion of specific dermoscopic structures within the total lesion area. These quantitative data were used to examine the relationship between dermoscopic features and histopathological findings.",[192],"Cutaneous Squamous Cell Cancer",[194,195,196,197,198,199,200],"dermoscopy","Dermoscopic features","Histopathology correlation","Tumor invasion depth","Skin cancer imaging","Computer-assisted image analysis","Squamous cell carcinoma","NOT_YET_RECRUITING","2026-01-27",{"date":204,"type":38},"2026-02-03",{"date":206,"type":22},"2026-02-01",{"date":208,"type":22},"2026-06",{"name":44,"class":45},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":16,"sex":127,"minAge":18,"maxAge":217,"enrollmentInfo":218,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":240,"leadSponsor":242,"locationsCount":46},"100620866","nailfold-capillaroscopy-and-endothelial-biomarkers-in-healthcare-workers-exposed-to-chronic-low-dose-ionizing-radiation-100620866","NCT07363187","Nailfold Capillaroscopy and Endothelial Biomarkers in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation","Evaluation of Microvascular Changes by Nailfold Capillaroscopy and Serum ADMA, Von Willebrand Factor, Hs-CRP, and D-dimer Levels in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation","Inclusion Criteria:\n\n* Healthcare workers aged between 18 and 60 years.\n* For the control group: Employment in a healthcare institution with either occupational exposure to low-dose ionizing radiation or no occupational radiation exposure.\n* For the exposed group: chronic occupational exposure to ionizing radiation for at least 3 years.\n* Willingness and ability to provide written informed consent.\n* Ability to comply with study procedures, including nailfold capillaroscopy and blood sample collection.\n\nExclusion Criteria:\n\n* History of cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.\n* Presence of systemic diseases that may affect microvascular structure or endothelial function, including diabetes mellitus, uncontrolled hypertension, dyslipidemia, or chronic kidney disease.\n* Known autoimmune, connective tissue, or systemic inflammatory diseases (e.g., systemic sclerosis, lupus erythematosus, vasculitis).\n* Active infection or acute inflammatory condition at the time of enrollment.\n* Use of systemic medications that may affect endothelial function or microcirculation within the past 4 weeks, including vasodilators, antihypertensive agents, statins, antiplatelet or anticoagulant drugs.\n* Current smoking or history of smoking within the past 6 months.\n* Pregnancy or breastfeeding.\n* History of malignancy or current cancer treatment.\n* Previous finger trauma, surgery, or local conditions affecting the nailfold area that may interfere with capillaroscopic evaluation.","60 Years",{"count":219,"type":22},90,"Chronic occupational exposure to low-dose ionizing radiation may lead to subclinical endothelial dysfunction and early microvascular alterations in healthcare workers. Nailfold capillaroscopy is a non-invasive method that allows direct visualization of microcirculatory changes. This observational study aims to evaluate microvascular alterations using nailfold capillaroscopy and to assess their association with serum endothelial and inflammatory biomarkers, including asymmetric dimethylarginine (ADMA), von Willebrand factor (vWF), high-sensitivity C-reactive protein (hs-CRP), and D-dimer levels. Healthcare workers with chronic low-dose radiation exposure will be compared with non-exposed controls. The study seeks to improve understanding of early vascular effects of occupational radiation exposure.",[222,223,224],"Microvascular Dysfunction","Endothelial Dysfunction","Occupational Radiation Exposure",[226,227,228,229,230,231,232,233,234,235],"Nailfold capillaroscopy","Microvascular changes","Low-dose ionizing radiation","Occupational radiation exposure","Healthcare workers","Endothelial dysfunction","Inflammation biomarkers","D-dimer","High-sensitivity C-reactive protein","Asymmetric dimethylarginine","2026-01-22",{"date":238,"type":38},"2026-01-26",{"date":206,"type":22},{"date":241,"type":22},"2026-05-01",{"name":44,"class":45},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":127,"minAge":18,"maxAge":128,"enrollmentInfo":250,"targetDuration":4,"studyType":101,"phases":252,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":46},"100604529","effects-of-close-follow-up-on-patients-with-low-back-pain-100604529","NCT07150702","Effects of Close Follow-up on Patients With Low Back Pain","The Effect of Close Follow-up by a Physician in Addition to a Conventional Physical Therapy Program in Patients With Low Back Pain","Inclusion Criteria:\n\n* Patients aged 18-65 with subacute or chronic mechanical back pain and considered appropriate for a physical therapy program.\n\nExclusion Criteria:\n\n* Patients describing inflammatory back pain\n* Spondyloarthropathies and other rheumatological diseases\n* History of spinal surgery\n* Patients with sensory disturbances and psychiatric diagnoses\n* Fibromyalgia\n* Patients with malignancies\n* Patients with active infectious findings\n* Patients with a history of radiotherapy",{"count":251,"type":22},74,[103],"This study will include patients aged 18-65 with subacute or chronic mechanical low back pain who apply to the Physical Medicine and Rehabilitation Clinic. The age, gender, body mass index, duration of low back pain, smoking status, and educational status of the patients included in the study will be recorded. Patients will be randomized into two groups: the study group and the control group. First, the psychosocial risk status of patients in both groups will be determined using the STarT Back Screening Tool. Then, patients in the control group will undergo a conventional physical therapy program that includes hot packs, transcutaneous electrical nerve stimulation, ultrasound, and core stabilization exercises. Patients in the study group will undergo daily close follow-up physician-patient meetings during the sessions, in addition to the conventional physical therapy program applied to the control group. Clinical assessments will be performed using the Visual Analogue Scale (VAS), Tampa Scale of Kinesiophobia, Pain Catastrophizing Scale, Beck's Depression Scale, Roland-Morris Disability Questionnaire, and Leeds Assessment of Neuropathic Symptoms and Signs. Clinical evaluations will be conducted at baseline, on Day 5 post-treatment, and at 1 month post-treatment.",[255,256],"Low Back Pain","Low Back Pain, Mechanical",[258,259,260,261],"low back pain","physical therapy","mechanical low back pain","pain management","2025-09-13",{"date":264,"type":38},"2025-09-16",{"date":266,"type":38},"2025-09-01",{"date":268,"type":22},"2025-12-10",{"name":44,"class":45},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":101,"phases":279,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":46},"100593174","immun-checkpoint-washout-in-patients-with-invasive-ductal-breast-cancer-100593174","NCT07003009","Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer","Detection of Lymph Node Positivity in Patients With Invasive Ductal Breast Cancer Using Immun Checkpoint Washout","Inclusion Criteria:\n\n* Histopathologically proven invasive ductal carcinoma\n* Patients who will have neoadjuvant therapy\n\nExclusion Criteria:\n\n* The fine-needle aspiration biopsy (FNAB) result of the suspected metastatic lymph node is negative.\n* The FNAB result of the presumed healthy lymph node is malignant.\n* They refuse to participate in the study.\n* They have another primary malignancy.\n* They are pregnant.\n* They have a history of immunodeficiency.",{"count":278,"type":22},30,[103],"Invasive ductal carcinoma is the most common type of invasive breast cancer. In cases where axillary lymph node metastases are diagnosed through screening, they can be found in up to 25% of cases, and in symptomatic cases, up to 60% of cases. The clinical detection accuracy of axillary lymph node metastases is only 33%. Accurate staging of lymph nodes in breast cancer patients is crucial for both prognosis and treatment. Ultrasonography is much more sensitive than physical examination alone for determining axillary lymph node involvement in breast cancer staging. Fine needle aspiration biopsy or core biopsy is diagnostic in lymph nodes that cannot be clarified solely by ultrasonography or are suspicious. Although biopsy sampling yields high diagnostic rates, it requires an experienced pathologist and sometimes takes weeks to yield results. Therefore, there is a need for faster and less costly diagnostic methods for diagnosing axillary metastases. Among thyroid cancers, papillary thyroid carcinomas, a malignancy in which the lymph node washout method is used to determine lymph node metastasis, are the most common. In papillary thyroid cancer patients, washout sampling of neck lymph nodes by fine needle aspiration, searching for thyroglobulin, a protein normally found in thyroid tissue, is considered one of the most valid methods for detecting lymph node metastasis in this cancer. In recent years, immune checkpoint molecules associated with cancer have been widely used as biomarkers and agents in both diagnosis and treatment for cancer patients. There are numerous publications in the literature regarding the expression of immune checkpoint molecules such as Programmed cell death protein 1 (PD-1), Programmed death ligand 1 (PD-L1), and The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) on the cell surface of breast cancer patients. Although the natural soluble forms of receptors and ligands of immune checkpoint molecules exist and they are important components of immune regulation, their exact mechanisms of action have not yet been determined. There are five studies in the literature evaluating the status of soluble immune checkpoint molecules in breast cancer patients, with one being a review article. It is highly likely that immune checkpoint molecules found on both the cell surface and soluble in blood and body fluids are also present in tumor metastatic regions. There is no study using these immunological biomarkers to determine metastasis in invasive ductal carcinoma patients with metastatic axillary lymph nodes ın the literature. In this study, the investigators will evaluate the soluble levels of immune checkpoint molecules in washout fluids obtained from metastatic axillary lymph nodes and benign lymph nodes in patients with invasive ductal breast carcinoma, and will assess the effectiveness of these immune checkpoint molecules and the washout method in diagnosing metastasis.",[282,283],"Breast Cancer Metastatic","Breast Carcinoma",[285,286,287,288],"Immune checkpoints","Breast Cancer","Lymph node","Washout","2025-05-31",{"date":291,"type":38},"2025-06-04",{"date":293,"type":38},"2024-01-01",{"date":295,"type":22},"2025-10-01",{"name":44,"class":45},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":127,"minAge":304,"maxAge":23,"enrollmentInfo":305,"targetDuration":4,"studyType":101,"phases":307,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":201,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":46},"100550444","continuous-versus-bolus-feeding-in-neonates-with-hypoxic-ischemic-encephalopathy-100550444","NCT06447155","Continuous Versus Bolus Feeding in Neonates With Hypoxic Ischemic Encephalopathy","The Impact of Continuous Versus Bolus Feeding in Neonates With Hypoxic Ischemic Encephalopathy Undergoing Therapeutic Hypothermia","Inclusion Criteria:\n\n* The neonates with evidence of encephalopathy de¬fined by seizures or abnormalities on a modified Sarnat exam were enrolled. The hypoxic-ischemic injury was defined by 1. a pH of ≤ 7.0 and\u002For 2. base deficit \\>-16 mmol\u002FL recorded in cord blood or blood gas obtained within the first hour postnatally or a pH of 7.0 - 7.15 and\u002For base deficit (-10-15.9) mmol\u002FL with the presence of an acute perinatal event (cord prolapse, placental abruption, heart rate decelerations, severe fetal bradycardia). In cases where criteria 1 or 2 are met, with the presence of seizures or a diagnosis of moderate to severe encephalopathy according to the Sarnat \\& Sarnat classification based on neurological examination were treated with TH.\n\nExclusion Criteria: Infants with congenital malformation or hereditary metabolic diseases, infants whose enteral feeding was initiated before randomization and infants without lack of parental consent were excluded. The maternal and neonatal demographic characteristics and clinical outcomes were collected from medical records.\n\n\\-","0 Days",{"count":306,"type":22},60,[103],"Therapeutic hypothermia (TH) is accepted worldwide as a standard of care for infants born at or beyond 36 weeks gestational age with moderate-to-severe hypoxic ischaemic encephalopathy (HIE).\n\nWhile central nervous system is the most affected organ system , multiorgan dysfunction including renal, pulmonary, cardiac, and\u002For gastrointestinal (GI) compromise is not infrequent. Although the process of 'cooling' itself is well defined, based on high-quality randomized controlled trials, there are few data to inform the provision of nutrition to infants with HIE during and soon after TH.However, breastfeeding plays a beneficial role in maintaining the structural and functional integrity of the gut. It may help to reduce systemic inflammatory response and positively regulates the microbiota. In many studies it is stated that enteral feeding during TH appears to be safe and feasible. There is insufficient evidence to choose the type of enteral feeding either bolus or continuous during TH.\n\nThe present study aimed to compare the impact of different types of enteral feeding in infants with HIE receiving TH.",[310,311],"Hypoxic Ischemic Encephalopathy of Newborn","Feeding Patterns",[313,314,315,316,317],"Newborn","Hypoxic ischemic encephalopathy","Enteral feeding","Bolus","Continuous","2024-06-03",{"date":320,"type":38},"2024-06-06",{"date":322,"type":22},"2024-06-15",{"date":324,"type":22},"2026-06-15",{"name":44,"class":45},""]